Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

40.31 +0.01 (+0.02%)

Official Closing Price Updated: 7:00 PM EST, Nov 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

2 Growth Stocks to Buy in November Without Any Hesitation ↗

November 05, 2026

They have both outperformed the broader equity market over the long run.

Via The Motley Fool

Novo Nordisk: 3 Key Takeaways for Long-Term Investors ↗

November 04, 2026

U.S. pricing pressure weighs on Novo Nordisk's growth, but management is counting on the pipeline to offset it over the long haul.

Via The Motley Fool

Topics Earnings Intellectual Property

Novo Nordisk (NVO) Q3 2026 Earnings Call Transcript ↗

November 04, 2026

Wegovy pill uptake and CagriSema trial results shape the growth recovery story.

Via The Motley Fool

Topics Earnings

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. ↗

November 04, 2026

Viking aims to enter the weight loss drug market.

Via The Motley Fool

3 Dirt Cheap Dividend Stocks to Buy in November 2026 ↗

November 03, 2026

These high-yielding stocks pay up to 7.4% in dividends.

Via The Motley Fool

Topics Economy

GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge? ↗

November 02, 2026

Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to...

Via MarketBeat

Topics ETFs

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗

November 02, 2026

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Via The Motley Fool

UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case. ↗

November 02, 2026

Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.

Via The Motley Fool

Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom? ↗

November 01, 2026

Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.

Via The Motley Fool

Novo Has Big Plans for 2030. Should You Buy the Stock Now? ↗

October 29, 2026

The company’s comeback strategy looks sound.

Via The Motley Fool

Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026? ↗

October 27, 2026

Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.

Via The Motley Fool

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts ↗

October 26, 2026

MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.

Via MarketBeat

Topics Artificial Intelligence

Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatility ↗

October 22, 2026

Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.

Via The Motley Fool

Where Will Novo Stock Be in 10 Years? ↗

October 21, 2026

The company may lean on its core therapeutic area to help it overcome recent headwinds.

Via The Motley Fool

Topics Intellectual Property

Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock? ↗

October 21, 2026

Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.

Via The Motley Fool

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗

October 18, 2026

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Via The Motley Fool

Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade? ↗

October 18, 2026

Novo is facing some headwinds, but it has a plan to overcome them.

Via The Motley Fool

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher ↗

October 16, 2026

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

Via The Motley Fool

Novo Nordisk and Eli Lilly Just Got Some Fantastic News ↗

October 16, 2026

A new government-funded study found that GLP-1 drugs slow the aging process in mice.

Via The Motley Fool

AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 13, 2026

One faces patent cliffs and revenue concentration; the other dominates a booming market but trades at a premium valuation.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. ↗

October 13, 2026

This pharma stock has climbed in the triple digits in recent years.

Via The Motley Fool

4 Healthcare Stocks Worth Owning for the Next Decade ↗

October 12, 2026

Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.

Via The Motley Fool

Topics Intellectual Property

As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze ↗

October 11, 2026

The weight-loss drugs are growing in popularity and altering consumer behavior in significant ways.

Via The Motley Fool

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 10, 2026

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

Via The Motley Fool

UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument. ↗

October 08, 2026

UBS analyst Michael Yee called Novo Nordisk a value trap, but still sees a turnaround playing out over time.

Via The Motley Fool

Only 20 Stocks Are Holding Up the Market: 3 Bargains Outside AI ↗

October 08, 2026

Stansberry Research's Whitney Tilson argues record highs mask a bifurcated market, favoring Joby Aviation, Casey's General Stores, and Eli Lilly as value picks outside the AI trade.

Via MarketBeat

Topics Artificial Intelligence

Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound ↗

October 07, 2026

The company is far from a one-trick pony.

Via The Motley Fool

Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity? ↗

October 06, 2026

Novo Nordisk has a huge opportunity in GLP-1 weight-loss drugs, but it has to prove it can use that success to build for the future.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 06, 2026

Eli Lilly's revenue surged 44.7% in 2025, but Novo Nordisk trades at less than a quarter of its valuation multiple, a stark contrast that reshapes the risk-reward calculus.

Via The Motley Fool

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? ↗

October 04, 2026

Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novo Nordisk A/S Common Stock (NY:NVO)

Headline News about Novo Nordisk A/S Common Stock

Starting at /week.